Filing summary: Point Capital, Inc. (not Silo Pharma, Inc.)
Reporting period: Fiscal year ended December 31, 2013; filed March 31, 2014. The filing identifies the registrant as Point Capital, Inc., formerly Gold Swap Inc. It is not a quarterly report, although it includes selected data for the fourth quarter of 2013.
Business context
Point Capital changed from a contemplated precious-metals business to a closed-end, non-diversified investment company and elected business development company (BDC) status in October 2013. Its stated objective is current income and capital appreciation through investments in smaller companies. It held two portfolio-company positions at year-end: Intercloud Systems and CombiMatrix.
Financial performance and position
- Investment income: $625 for 2013, including $600 of interest from the Intercloud debenture. This is investment income, not conventional operating revenue.
- Expenses and earnings: Operating expenses were $72,611, producing a net investment loss of $71,986. A $39,754 realized investment gain and $65,143 net unrealized appreciation brought the net increase in net assets from operations to $32,911. The filing reports 2012 and 2011 net losses of $39,446 and $49,803, respectively.
- Fourth quarter: Investment income was $600; net investment loss was $20,883; realized gain was $39,754 and unrealized appreciation was $65,143. The resulting quarterly increase in net assets from operations was $84,014.
- Portfolio and valuation: Investments had a reported cost of approximately $131,021 and fair value of $196,164 at year-end, equal to 10.97% of net assets. The filing’s balance sheet note gives cost as $131,023, so the cost figure is inconsistent in the filing. $147,231 of investments were Level 3 fair value measurements, with valuation inputs including a 50% restriction discount.
- Liquidity and cash flow: Year-end cash was $2,010,620; total assets were $2,207,384; and net assets were $1,788,667. Operating cash used was $181,609, offset by $2,191,950 of financing cash inflows, leaving cash up $2,010,341 for the year. Management said available cash was expected to cover working-capital needs for at least 12 months.
- Debt and preferred stock: Year-end liabilities were $18,717, including $15,000 of unsecured notes payable. The notes were repaid in January 2014, after which the company reported no other debt. Separately, $400,000 of redeemable Series A preferred stock was presented as temporary equity, not as a liability.
- Shareholder returns: No common dividends had been declared or paid. Year-end common shares outstanding were 40,606,200; 48,382,440 were reported outstanding as of March 31, 2014.
Changes and financing
- The company moved from development-stage status and its former Gold Swap identity to a BDC investment strategy in 2013. It began investing during the fourth quarter.
- Operations improved from losses in 2012 and 2011 to a small 2013 operating increase, driven by realized and unrealized investment gains rather than investment income; the company still had a net investment loss.
- In 2013, it issued 9,975,000 common shares for $1,995,000 gross proceeds and issued Series A preferred stock for $400,000. The filing says $1,975,000 had closed under a placement-agency arrangement by December 26, 2013, but reports $2,305,000 closed by the filing date. It also reports a January 2014 common-stock raise of $330,000.
- In March 2014, the placement agent received 6,126,240 common shares as offering compensation. The filing values these shares at $1,225,248 using $0.20 per share and records the amount as a reduction of offering proceeds. This is a substantial dilution and offering-cost item after year-end.
Outlook, risks, and unusual items
- The investment strategy emphasizes senior loans, with about 65% of future net assets (including investment borrowings) expected to be allocated to them under normal conditions. The company planned to elect regulated investment company (RIC) tax treatment in 2014; it had not yet done so for the reporting year.
- The company disclosed that it was not in compliance with some BDC rules, including a non-majority-independent board, and described its custody of restricted portfolio securities in a locked company safe under the CFO’s sole custody as not compliant with the Investment Company Act custody requirements. Loss of BDC status or forced investment sales could materially harm operations.
- Disclosure controls were deemed ineffective, and management identified material weaknesses involving accounting expertise, board and audit-committee independence, segregation of duties, and period-end financial reporting. Management planned remediation during 2014. The auditor did not provide an internal-control attestation.
- Other key risks include dependence on a small, part-time management team; limited operating history and investment diversification; illiquidity and uncertain fair values of investments; competition; possible future dilution; and the preferred holder’s conversion, redemption, voting, and other rights. The filing also warns of risks to RIC qualification and required distributions.
- The company reported no pending material legal proceedings and no off-balance-sheet arrangements. The 2012 auditor had raised substantial doubt about the company’s ability to continue as a going concern; the 2013 auditor issued an unmodified financial-statement opinion. These are different reporting periods and should not be conflated.
Important facts for investors to verify
- Confirm the issuer identity: this filing is for Point Capital, Inc., not Silo Pharma, Inc.
- Reconcile the reported investment cost of $131,021 versus $131,023 and verify the valuation basis, particularly the Level 3 debenture and restriction discount.
- Reconcile financing proceeds, placement-agent fees, the reported $2.305 million raised by filing date, and the 6,126,240 agent shares and their dilution impact.
- Check the company’s subsequent remediation of BDC compliance, securities custody, board independence, and internal-control weaknesses, as well as whether it completed its planned 2014 RIC election.
- Assess the liquidity runway against ongoing expenses and cash use, and review the preferred stock’s redemption triggers, conversion terms, and asset-coverage implications.